



Press Release, September 16, 2020

Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2

Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about half of all type 1 diabetes patients. In connection to this, CEO Ulf Hannelius together with the trial's Coordinating Investigator Professor Johnny Ludvigsson and Professor Mark Atkinson will hold a webcast presentation on Thursday 17 September at 15.00 CET.

The presentation is hosted by News Agency Direkt and Direkt Studios and can be watched at

<https://youtu.be/UH6sr8WIbaQ>

About Diamyd Medical

Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined subgroup in a large-scale metastudy as well as in the Company's European Phase IIb trial DIAGNODE-2, where the diabetes vaccine is administered directly into a lymph node in children and young adults with newly diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd®. Diamyd Medical also develops the GABA-based investigational drug Remygen® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical's B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se.

For further information, please contact:

Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)

Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: <https://www.diamyd.com>

The information was submitted for publication, through the agency of the contact person set out above, at 12.45 CET on September 16, 2020.